Mucosal [SIgA] and serum [IgG] immunologic responses in the community after a single intra-nasal immunization with a new inactivated trivalent influenza vaccine

Vaccine

Volumn 20, Issue 7-8, 2002, Pages 1232-1239

  Greenbaum, Evgenia ^a   Furst, Arthur ^a   Kiderman, Alexander ^a   Stewart, Brendon ^a   Levy, Reuven ^a   Schlesinger, Miriam ^a   Morag, Avraham ^b   Zakay Rones, Zichria ^a  

^a HEBREW UNIVERSITY   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

HAI titer increase; Inactive intra nasal trivalent influenza vaccine; Mucosal antibody response; Serum antibody response

Indexed keywords

IMMUNOGLOBULIN A; INACTIVATED VACCINE; INFLUENZA VACCINE; PLACEBO; TRIPLE VACCINE;

ADOLESCENT; ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CLINICAL TRIAL; COMMUNITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ECONOMIC ASPECT; FEMALE; HEMAGGLUTINATION; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; INFECTION PREVENTION; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MUCOSAL IMMUNITY; PRIORITY JOURNAL; SCHOOL CHILD; VACCINATION; VIRUS STRAIN;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; FEMALE; HUMANS; IMMUNIZATION; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; INFLUENZA VACCINES; MALE; MIDDLE AGED; NASAL MUCOSA; PROSPECTIVE STUDIES;

EID: 0037081380     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00396-6     Document Type: Article

References (54)

1. Center for Disease Control and Prevention and Control of Influenza: Recommendations of the advisory committee on immunization (ACIP)
2. Influenza vaccination among healthy employees: A cost-benefit analysis
3. The socio-economic impact of influenza
4. Orthomyxoviruses
5. Failure of influenza vaccination in the aged
6. Antibody response to a two dose regimen of influenza vaccine in allogeneic T cell-depleted autologous BMT recipients
7. Antibody response to influenza immunization in patients after heart transplantation
8. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature
9. Local and systemic immune response in community dwelling elderly after intra-nasal or intra-muscular immunization with inactivated influenza vaccine
10. Influenza vaccines: Present and future advances
11. Developments in mucosal influenza viurs vaccines
12. Secretory antibody response following oral influenza immunization
13. Immune responses in serum and respiratory secretions following vaccination with a live cold-recombinant (CR35) and inactivated A/USSR/77(H1N1) influenza virus vaccine
14. Protection against influenza virus infection by vaccine inoculated intra-nasally with cholera toxin B subunit
15. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intra-nasally to healthy adults
16. The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intra-nasally in mice
17. A novel influenza subunit vaccine composed of liposome-encapuslated haemagglutinin/neuradminidase and IL-2 or GM-CSF. Part I. Vaccine characterization and efficacy studies in mice
18. A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuradminidase and IL-2 or GM-CSF. Part II. Induction of TH1 and TH2 responses in mice
19. Immunogenicity of new virosome influenza vaccine in elderly people
20. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs)
21. Influenza virus subtype cross-reactivities of haemagglutination inhibiting and virus neutralizing serum antibodies induced by infection or vaccination with an ISCOM-based vaccine
22. Mucosal immune response to trivalent live attenuated intra-nasal influenza vaccine in children
23. Systemic and local antibody responses in elderly subjects given live or inactiated influenza A virus vaccines
24. In elderly persons live attenuated influenza virus vaccines do not offer an advantage over inactivated virus vaccine in inducing serum or secretory antibodies or local immunologic memory
25. The efficacy of live attenuated cold-adapted trivalent intra-nasal influenza virus vaccine in children
26. Serum and mucosal immunologic responses in children following the administration of a new inactivated intra-nasal anti influenza vaccine
27. A double-blind trial of a new inactivated, trivalent, intra-nasal anti-influenza vaccine in general practice: Relationship between immunogenicity and respiratory morbidity over the winter of 1997-1998
28. Effects of repeated annual influenza vaccination on vaccine sero response in young and elderly adults
29. Enzyme immunoassays in diagnostic medicine
30. The geometric mean confidence limits and significance-tests
31. Protective effects of nasal adjuvant-combined influenz vaccine
32. Emerging infections; pandemic influenza
33. The impact of influenza epidemics on mortality; introducing a severity index
34. Influenza vaccines
35. Phase I clinical tests of influenza MDP - Virosome vaccine (KD-5382)
36. Dehydroepiandrosterone treatment is not beneficial to the immune response to influenza in elderly subjects
37. Dehydroepiandrosterone (DHEA) treatment reverses the impaired immune response of old mice to influenza vaccination and protects from influenza infection
38. Local and peripheral cell mediated immune response to influenza virus in mice
39. Induction of antigen specific antibodies in vaginal secretions by using a nontoxic mutant of heat labile enterotoxin as a mucosal adjuvant
40. Modified M2 proteins produce heterotypic immunity against influenza A virus
41. Whole virus influenza vaccine activates dendritic cells (DC) and stimulates cytokine production by peripheral blood mononuclear cells (PBMC) while subunit vaccines support T cell proliferation
42. The immune response to influenza infection
43. Persistence of influenza as an immunogen in pulmonary antigen-presenting cells
44. The binding of chimeric peptides to GM1 gangliosides enables induction of antibody responses after intransal immunization
45. Functional role of respiratory tract haemagglutinin-specific IgA antibodies in protection against influenza
46. Cross-protection against influenza virus infection afforted by trivalent inactivated vaccines inoculated intra-nasally with cholera toxin B subunit
47. Centers of Disease Control Prevention and Control of Influenza
48. The efficacy of live attenuated cold-adapted trivalent intransal influenzavirus vaccine in children
49. Influenza virus infections and immunity: A review of human an animal models
50. Safety and immunogenicity of a 45 μg supplemental dose of inactivated split-virus influenza B vaccine in the elderly
51. Secretory immunological response after intra-nasal inactivated influenza A virus vaccinations: Evidence for immunoglobulin A memory
52. Immunization of elderly people with high doses of influenza vaccine